ロード中...
The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer
First- and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the evidence-based first-line treatment for metastatic non-small-cell lung cancers (NSCLCs) that harbor sensitizing EGFR mutations (i.e., exon 19 deletions or L858R). However, acquired resistan...
保存先:
| 出版年: | Expert Rev Anticancer Ther |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4940973/ https://ncbi.nlm.nih.gov/pubmed/26943236 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/14737140.2016.1162103 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|